Fact based stock research
Takeda Pharmaceutical (TSE:4502)

Takeda Pharmaceutical stock research in summary

Takeda Pharmaceutical shares are cheaper than other comparable stocks. They are good value and show above average growth, but are riskily financed. We recommend evaluating if the future of the company Takeda Pharmaceutical is really as difficult as the low price of the shares suggests. If you believe that the future of the company is market-typical or even better, then this would be an argument for a share purchase.

Latest Obermatt Ranks


Value Rank	81
Growth Rank	71
Safety Rank	13
Combined Rank	60

Country	Japan
Industry	Pharmaceuticals
Index	Nikkei 225, TOPIX 100
Size class	XX-Large

April 19, 2019. Stock data may be delayed. Login to get the most recent research.

☀ Achievements

Top 10 Stock	Top 10 Focus Stock
Climate Protection Stock	Family Friendly

Google: Takeda Pharmaceutical

News	Videos
Wikipedia about Takeda Pharmaceutical	Management
Employee Satisfaction	Customer Satisfaction

Add to Watchlist

Similar Stocks

All Top 10 Lists

Research History: Takeda Pharmaceutical

RESEARCH HISTORY	2016	2017	2018	2019
VALUE
VALUE	98	91	89	81
GROWTH
GROWTH	39	66	71	71
SAFETY
SAFETY	40	21	38	13
COMBINED
COMBINED	63	80	100	60

Last update of Combined Rank: 19-Apr-2019. Stock research history is based on the Obermatt Method. The higher the rank, the better Takeda Pharmaceutical is in the corresponding investment strategy.

Value Metrics in Detail

VALUE METRICS	2016	2017	2018	2019
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)	77	66	66	55
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)	67	68	44	44
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)	82	72	80	73
DIVIDEND YIELD
DIVIDEND YIELD	96	96	96	98
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE	98	91	89	81

Last update of Value Rank: 19-Apr-2019. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Takeda Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.

Growth Metrics in Detail

GROWTH METRICS	2016	2017	2018	2019
REVENUE GROWTH
REVENUE GROWTH	28	19	33	91
PROFIT GROWTH
PROFIT GROWTH	75	75	71	89
STOCK RETURNS
STOCK RETURNS	35	82	57	12
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH	39	66	71	71

Financial reporting date of Growth Rank: 31-Dec-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Takeda Pharmaceutical.

Safety Metrics in Detail

SAFETY METRICS	2016	2017	2018	2019
LEVERAGE
LEVERAGE	21	20	12	10
REFINANCING
REFINANCING	76	28	28	82
LIQUIDITY
LIQUIDITY	36	38	62	16
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY	40	21	38	13

Financial reporting date of Safety Rank: 31-Dec-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Takeda Pharmaceutical and the more cash is available to service its debt.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Takeda Pharmaceutical from April 19, 2019.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.